drugset / Trial / NCT00814710

Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age

NCT00814710

Phase 3 Completed 360 enrolled GlaxoSmithKline
RandomizedParallel-groupSingle-blindPrevention

Summary

The purpose of this study is to assess the immunogenicity in terms of antibody response and the safety/reactogenicity in terms of solicited and unsolicited symptoms and serious adverse events following primary vaccination of Indian infants with pneumococcal conjugate vaccine GSK1024850A co-administered with a diphtheria, tetanus, whole cell pertussis (DTPw)-combined vaccine during the first 4 months of life. The study will be conducted in India.

Timeline

Start
2009-03-07
Primary completion
2009-11-13
Completion
2009-11-13

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK1024850A Vaccine Intramuscular
Comparator HAEMOPHILUS INFLUENZAE TYPE B STRAIN 20752 CAPSULAR POLYSACCHARIDE TETANUS TOXOID CONJUGATE ANTIGEN Vaccine Intramuscular
Comparator Tritanrix-HepB Vaccine Intramuscular
Subject Tritanrix-HepB/Hib Unknown Intramuscular